Skip to main content
. 2024 Mar 4;16:1329551. doi: 10.3389/fnagi.2024.1329551

TABLE 1.

Anosmia vs. non-anosmia: initial comparison based on first visit and aggregate of the three visits with ≥2 clinical assessments.

Visit 1 Visit 2 Visit 3
Anosmia n = 32 Non-anosmia n = 26 p Anosmia n = 25 Non-anosmia n = 19 Anosmia n = 10 Non-anosmia n = 11
Age, year 64 (61–70) 66 (58–74) 0.956 65 (60–71) 65 (59–77) 73 (65–81) 66 (60–69)
Sex, male (%) 23 (72%) 17 (65%) 0.776 18 (72%) 11 (58%) 7 (70%) 9 (82%)
Sex, female (%) 9 (28%) 9 (35%) 7 (28%) 8 (42%) 3 (30%) 2 (18%)
Duration, month 49 (27–108) 31 (12–56) 0.043* 79 (58–131) 52 (29–71) 59 (34–107) 64 (44–100)
Follow-up, month 0 (0–0) 0 (0–0) 1.000 16 (14–21) 15 (14–22) 26 (25–30) 29 (26–34)
LEDD, mg 655 (175–937) 250 (108–457) 0.009* 798 (423–1297) 400 (250–639) 724 (433–1023) 524 (400–948)
UPSIT 14 (12–16) 22 (20–25) 0.000* 12 (10–15) 21 (18–24) 13 (11–15) 21 (18–23)
MOCA 27 (21–29) 28 (24–29) 0.374 24 (20–28) 27 (23–29) 23 (14–27) 28 (27–29)
M-UPDRS
Total 54 (37–72) 44 (31–57) 0.051 50 (37–82) 47 (34–53) 59 (48–64) 55 (24–63)
Part III 34 (21–42) 25 (18–35) 0.057 31 (23–42) 29 (23–36) 38 (33–43) 30 (17–33)
PDQ-39
SI 19 (9–30) 19 (6–30) 0.690 14 (6–33) 14 (9–27) 18 (8–41) 19 (7–30)
ADL 13 (1–29) 6 (0–23) 0.211 13 (0–27) 4 (0–21) 15 (0–31) 4 (0–21)
COG 25 (14–44) 19 (11–39) 0.299 19 (6–47) 19 (0–38) 28 (9–56) 25 (13–56)

Data are presented as median (Q1–Q3), with “duration” denoting time since symptom onset and “follow-up” representing time from initial visit. Anosmia: baseline UPSIT < 19; Non-anosmia: baseline UPSIT ≥ 19. ADL, activities of daily living; COG, cognitions; LEDD, levodopa equivalent daily dose; MoCA, Montreal cognitive assessment; M-UPDRS, movement disorder society-sponsored revision of the Unified Parkinson’s Disease Rating Scale; PDQ-39, Chinese-translated version of 39-item Parkinson’s Disease Questionnaire; SI, summary index; UPSIT, traditional Chinese version of the University of Pennsylvania Smell Identification Test.

*p < 0.05.